Log in
Enquire now

List of Fox Chase Cancer Center (company) patents

List of Fox Chase Cancer Center (company) patents
List of Elekta patents
List of Personalis patents
List of Ikena Oncology patents
List of funding rounds for PetDesk
Companies in the Social recruiting industry
Patents where
Current Assignee
Name
is
Fox Chase Cancer Center (company)Fox Chase Cancer Center (company)
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 7618817 Genetically modified human natural killer cell lines

Patent 7618817 was granted and assigned to Fox Chase Cancer Center (company) on November, 2009 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7618817
November 17, 2009
‌
US Patent 7317192 High energy polyenergetic ion selection systems, ion beam therapy systems, and ion beam treatment centers

Patent 7317192 was granted and assigned to Fox Chase Cancer Center (company) on January, 2008 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7317192
January 8, 2008
‌
US Patent 7615528 Methods for alleviating deleterious effects of 3-deoxyglucosone

Patent 7615528 was granted and assigned to Fox Chase Cancer Center (company) on November, 2009 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7615528
November 10, 2009
‌
US Patent 9181322 Genetically modified human natural killer cell lines

Patent 9181322 was granted and assigned to Fox Chase Cancer Center (company) on November, 2015 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
9181322
November 10, 2015
‌
US Patent 9150636 Genetically modified human natural killer cell lines

Patent 9150636 was granted and assigned to Fox Chase Cancer Center (company) on October, 2015 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
9150636
October 6, 2015
‌
US Patent 7268358 Method of modulating laser-accelerated protons for radiation therapy

Patent 7268358 was granted and assigned to Fox Chase Cancer Center (company) on September, 2007 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7268358
September 11, 2007
‌
US Patent 7312026 MRP-related ABC transporter encoding nucleic acids and methods of use thereof

Patent 7312026 was granted and assigned to Fox Chase Cancer Center (company) on December, 2007 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7312026
December 25, 2007
‌
US Patent 7199122 Methods for inhibiting angiogenesis

Patent 7199122 was granted and assigned to Fox Chase Cancer Center (company) on April, 2007 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7199122
April 3, 2007
‌
US Patent 7208583 Antibodies immunologically specific for a DNA repair endonuclease and methods of use thereof

Patent 7208583 was granted and assigned to Fox Chase Cancer Center (company) on April, 2007 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7208583
April 24, 2007
‌
US Patent 7491807 Gene encoding a DNA repair enzyme and methods of use thereof

Patent 7491807 was granted and assigned to Fox Chase Cancer Center (company) on February, 2009 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7491807
February 17, 2009
‌
US Patent 8313943 Genetically modified human natural killer cell lines

Patent 8313943 was granted and assigned to Fox Chase Cancer Center (company) on November, 2012 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
8313943
November 20, 2012
‌
US Patent 7736848 Cellular targets for treatment of retroviral infection

Patent 7736848 was granted and assigned to Fox Chase Cancer Center (company) on June, 2010 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7736848
June 15, 2010
‌
US Patent 10450613 EGFR/NEDD9/TGF-β interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders

Patent 10450613 was granted and assigned to Fox Chase Cancer Center (company) on October, 2019 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
10450613
October 22, 2019
‌
US Patent 8198411 Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer

Patent 8198411 was granted and assigned to Fox Chase Cancer Center (company) on June, 2012 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
8198411
June 12, 2012
‌
US Patent 7755068 Laser-accelerated proton therapy units and superconducting electromagnet systems for same

Patent 7755068 was granted and assigned to Fox Chase Cancer Center (company) on July, 2010 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7755068
July 13, 2010
‌
US Patent 8431527 Methods for alleviating deleterious effects of 3-deoxyglucosone

Patent 8431527 was granted and assigned to Fox Chase Cancer Center (company) on April, 2013 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
8431527
April 30, 2013
‌
US Patent 8329467 Compositions and methods for altering pancreas or liver function

Patent 8329467 was granted and assigned to Fox Chase Cancer Center (company) on December, 2012 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
8329467
December 11, 2012
‌
US Patent 7416840 Replication of hepatitis C virus in non-hepatic epithelial and mouse hepatic cells

Patent 7416840 was granted and assigned to Fox Chase Cancer Center (company) on August, 2008 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7416840
August 26, 2008
‌
US Patent 8802432 Methods and cell cultures for promoting organogenesis and tissue development

Patent 8802432 was granted and assigned to Fox Chase Cancer Center (company) on August, 2014 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
8802432
August 12, 2014
‌
US Patent 8748373 Hepatitis B virus compositions and methods of use

Patent 8748373 was granted and assigned to Fox Chase Cancer Center (company) on June, 2014 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
8748373
June 10, 2014
‌
US Patent 7452884 Methods for inhibiting angiogenesis

Patent 7452884 was granted and assigned to Fox Chase Cancer Center (company) on November, 2008 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7452884
November 18, 2008
‌
US Patent 9611321 Rationally-designed anti-mullerian inhibiting substance type II receptor antibodies

Patent 9611321 was granted and assigned to Fox Chase Cancer Center (company) on April, 2017 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
9611321
April 4, 2017
‌
US Patent 7829671 Gene encoding a DNA repair enzyme and methods of use thereof

Patent 7829671 was granted and assigned to Fox Chase Cancer Center (company) on November, 2010 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7829671
November 9, 2010
‌
US Patent 8653324 TetO-p16 transgenic mice

Patent 8653324 was granted and assigned to Fox Chase Cancer Center (company) on February, 2014 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
8653324
February 18, 2014
‌
US Patent 7705021 Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer

Patent 7705021 was granted and assigned to Fox Chase Cancer Center (company) on April, 2010 by the United States Patent and Trademark Office.

Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
United States Patent and Trademark Office
United States Patent and Trademark Office
7705021
April 27, 2010
Results per page:
28 results
0 selected
28 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us